CN110736832B - Composition for identifying spectrum cells by using antibody - Google Patents

Composition for identifying spectrum cells by using antibody Download PDF

Info

Publication number
CN110736832B
CN110736832B CN201911310553.6A CN201911310553A CN110736832B CN 110736832 B CN110736832 B CN 110736832B CN 201911310553 A CN201911310553 A CN 201911310553A CN 110736832 B CN110736832 B CN 110736832B
Authority
CN
China
Prior art keywords
cells
composition
antigens
antibody
sets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911310553.6A
Other languages
Chinese (zh)
Other versions
CN110736832A (en
Inventor
李小飞
陈燕
郎嵘
李小力
胡滨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Friendship Hospital
Original Assignee
Beijing Friendship Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Friendship Hospital filed Critical Beijing Friendship Hospital
Priority to CN201911310553.6A priority Critical patent/CN110736832B/en
Publication of CN110736832A publication Critical patent/CN110736832A/en
Application granted granted Critical
Publication of CN110736832B publication Critical patent/CN110736832B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells

Abstract

The invention provides a composition for identifying spectrum cells by using antibodies, and the compositionCompositions comprising at least 2 sets of selected cells, said compositions comprising antigens of the Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego and/or Lewis systems. The composition has the advantages that all spectrum cells complement each other, make good for each other and make up for each other's deficiencies, and not only contain few domestic Kell system antigens, Duffy system antigens, Mia antigens and FyaAntigens, in turn, comprise oriental-specific Diego system antigens. Furthermore, the results of quality evaluation in clinical blood transfusion compatibility detection rooms by adopting the composition are all AAA, the requirements of laws and regulations are met, the identification work of common laboratory antibodies can be met, and reagents are not wasted.

Description

Composition for identifying spectrum cells by using antibody
Technical Field
The invention relates to the technical field of antibody identification spectrum cells, in particular to a composition of an antibody identification spectrum cell.
Background
The blood group irregular antibody refers to blood group antibodies except anti-A and anti-B in serum, the antibodies are mostly IgG antibodies, are mainly generated by immune stimulation such as blood transfusion or pregnancy and are main factors causing immune hemolytic transfusion reaction, neonatal hemolytic disease, inconformity of blood grouping, incompatibility of cross matching and ineffective blood transfusion. Therefore, the screening and identification of serum irregular antibodies before transfusion are very important for the safety and effectiveness of transfusion. The frequency of irregular antibody to erythrocytes is reported in the literature to be 1% to 2% in hospital patients. In 2010, a 3-year-old survey in japan showed that the patient had a positive rate of anti-sieve of 1.43%. The detection rate of the irregular antibody of the red blood cells in the transfusion patient is reported to be 0.3-2.0%. The accuracy of screening and identifying the serum irregular antibody before transfusion is proved to be important.
Erythrocyte spectrum cells are reagent cells for identifying the specificity of irregular antibodies outside the ABO blood group system, and are formed by combining O-type erythrocytes (basic cells or background cells) with known antigen phenotypes of various blood group systems. The number of the cells is 3, and the number of the cells is 16. However, at present, there is no qualified identification cell in China for accurate and comprehensive identification, and the imported identification cell does not contain the specific antigen of oriental people, so that the requirement of clinically identifying the antibody cannot be met.
In the prior art, the research situation of screening the spectrum cells of the serum irregular antibody is as follows:
non-patent documents: the spectral cell detection of anti-e antibodies (Chuaiba et al, Hainan medicine, 2006) discloses that 3 kinds of spectral cells are firstly used for screening, and then 10 kinds of spectral cells are used for determinacy detection, so that it is determined that the patient really generates anti-e antibodies, and the red blood cells negative to e antigens must be transfused, and because the patient takes measures in time, no blood transfusion reaction occurs after several times of blood transfusions after the e antibodies are generated, the blood transfusion safety of the patient is ensured. However, there are probably more than 20 kinds of irregular antibodies produced by human, and the e antibody is far from enough to be screened.
Non-patent documents: screening and establishment of erythrocyte spectral cells (Diazao Ping Zhang et al, journal of inner Mongolia medicine 1999) disclosed screening 9 groups of O-type Rh phenotypes and 29 antigens by investigating Rh, Duffy, Kidd and other 12 blood group system antigens through a saline method, a papain method, an indirect Coombs method, neutralization, absorption, diffusion and other tests, and the spectral cell reaction patterns of the antigens are shown in the attached table. The spectrum cell not only can detect common blood type antibodies, but also can detect rare blood type antibodies, 18 antigens are complete in negative and positive, and about 10 antigens of Kell, Lutheran and Jr are incomplete in negative and positive.
Non-patent documents: establishment and clinical application of erythrocyte spectral cell (Roguangping et al, journal of practical medicine, 2002) disclose establishing a set of spectral erythrocytes capable of rapidly identifying specificity of blood group antibodies, screening 22 blood donors as spectral cell members to form 10 sets of spectral cells, each set of spectral cells contains more than 20 antigens, the distribution pattern of specific erythrocyte spectral cell antigens is shown in table 1, the spectral erythrocyte reagent has the advantages of more reasonable antigen distribution, strong antibody identification capability, convenient use and the like, but s and Fy still exist in table 1a、Fyb、k、Lua、LubAnd the like due to incomplete yin and yang.
Non-patent documents: red blood cellPreliminary studies on the establishment and preservation of spectral cells (Yangyefu et al, J. Modem. Med. 2003) disclose a spectral cell whose O-type spectral cell response pattern is shown in Table 1, showing that 15 antibodies can be identified, but there are still several antigens with incomplete yin and yang, including s and Fya、K、k、Kpa、Kpb、Lua、LubAnd the like.
Therefore, the method provides the antibody identification after the antibody identification cell spectrum is combined by a plurality of different screened cells based on the defects that the spectrum cells still contain identified antibody yin-yang incompleteness and identified cells without qualification are accurately and comprehensively identified, can effectively solve the problem of clinical antibody identification, and simultaneously screens the cells for antibody identification to avoid the waste of erythroblast reagents.
Disclosure of Invention
In order to solve the problem that in the prior art, the spectrum cell screened by the irregular antibody still contains a plurality of antigens, namely incomplete yin and yang, and the irregular antibody cannot be identified comprehensively and accurately. The application therefore provides a composition for identifying spectrum cells by using the antibody, which comprises at least 8 systematic antigens and more than 20 antigens, has complete negative and positive results and is accurately identified. Meanwhile, the composition provided by the application has the advantages that the spectrum cells complement each other, make up for deficiencies, and contain few domestic Kell system antigens, Duffy system antigens, Mia antigens and FyaAntigens, in turn, comprise oriental-specific Diego system antigens. Furthermore, the results of quality evaluation in clinical blood transfusion compatibility detection rooms by adopting the composition are all AAA, the composition meets the requirements of laws and regulations, the identification work of common laboratory antibodies can be met, reagents are not wasted, and great value is brought to hospitals.
The invention provides a composition of antibody identification spectrum cells, wherein the composition at least comprises 2 sets of screening cells, each set of screening cells comprises three sets of cells, and the composition contains antigens of Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego and/or Lewis systems.
Preferably, the composition comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 sets of the selected cells.
More preferably, the composition comprises at least 2, 3, 4 or 5 sets of selected cells.
In one embodiment of the invention, the composition comprises 3 or 4 sets of selected cells.
Preferably, the composition comprises antigens of the Rh-hr, MNSs, Kidd, Duffy and/or Lewis systems.
In one embodiment of the invention, the composition comprises antigens of the Rh-hr, MNSs, Kidd, Duffy and Lewis systems.
More preferably, the composition further comprises an antigen of the Kell, P and/or Diego system.
In one embodiment of the invention, the composition comprises antigens of the Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego and Lewis systems.
Preferably, the composition contains D, C, E, C, E and Jka、Jkb、M、N、S、s、Fya、Fyb、LeaAnd/or Leb。
In one embodiment of the present invention, the composition comprises D, C, E, C, E, Jka、Jkb、M、N、S、s、Fya、Fyb、LeaAnd Leb。
More preferably, the composition further comprises Mia, K, K, Kpa、KpbP1 and/or Dia。
In one embodiment of the present invention, the composition comprises D, C, E, C, E, Jka、Jkb、M、N、S、s、Fya、Fyb、Lea、Leb、Mia、K、k、Kpa、KpbP1 and Dia。
In one embodiment of the invention, the composition comprises 2 sets of selected cells having an antigen distribution pattern selected from any one of the following:
a）
Figure 131632DEST_PATH_IMAGE001
b）
Figure 435575DEST_PATH_IMAGE002
c）
Figure 38594DEST_PATH_IMAGE003
d）
Figure 478803DEST_PATH_IMAGE004
e）
Figure 195393DEST_PATH_IMAGE005
f）
Figure 721052DEST_PATH_IMAGE006
g）
Figure 65446DEST_PATH_IMAGE007
h）
Figure 360161DEST_PATH_IMAGE008
i）
Figure 194125DEST_PATH_IMAGE009
j）
Figure 207080DEST_PATH_IMAGE010
。
in one embodiment of the invention, the composition comprises 3 sets of selected cells having an antigen distribution pattern selected from any one of the following:
（1）
Figure 151903DEST_PATH_IMAGE011
（2）
Figure 504387DEST_PATH_IMAGE012
（3）
Figure 509252DEST_PATH_IMAGE013
（4）
Figure 9503DEST_PATH_IMAGE014
（5）
Figure 760946DEST_PATH_IMAGE015
（6）
Figure 30253DEST_PATH_IMAGE016
（7）
Figure 143703DEST_PATH_IMAGE017
（8）
Figure 131250DEST_PATH_IMAGE018
（9）
Figure 417875DEST_PATH_IMAGE019
。
in one embodiment of the invention, the composition comprises 4 sets of selected cells having an antigen distribution pattern selected from any one of the following:
A）
Figure 807268DEST_PATH_IMAGE020
B）
Figure 826040DEST_PATH_IMAGE021
C）
Figure 300884DEST_PATH_IMAGE022
D）
Figure 391199DEST_PATH_IMAGE023
。
in one embodiment of the invention, the composition comprises 5 sets of selected cells having the following antigen distribution pattern:
Figure 635099DEST_PATH_IMAGE024
the invention also provides a preparation method of the composition of the antibody identification spectrum cell, which comprises screening the spectrum cell or the spectrum cell group containing the antigen of Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego and/or Lewis system.
Preferably, the preparation method comprises screening the spectral cells or the group of spectral cells comprising the antigens of the Rh-hr, Kidd, MNSs, Duffy and/or Lewis systems.
In one embodiment of the invention, the method of preparation comprises screening the spectral cell or set of spectral cells for antigens comprising Rh-hr, MNSs, Kidd, Duffy and Lewis systems.
Further preferably, the preparation method further comprises screening the spectral cell or the group of spectral cells comprising the antigen of Kell, P and/or Diego system.
In one embodiment of the invention, the method of preparation comprises screening the spectral cells or groups of spectral cells for antigens comprising Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego and Lewis systems.
Preferably, the preparation method comprises screening the spectral cells or the group of spectral cells comprising the D, C, E, C, E, Jka, Jkb, M, N, S, S, Fya, Fyb, Lea and/or Leb antigens.
In one embodiment of the present invention, the preparation method further comprises screening the spectral cell or the group of spectral cells comprising the antigens D, C, E, C, E, Jka, Jkb, M, N, S, S, Fya, Fyb, Lea and Leb.
Further preferably, the preparation method further comprises screening the spectral cell or the group of spectral cells containing the Mia, K, K, Kpa, Kpb, P1 and/or Dia antigen.
In one embodiment of the invention, the preparation method comprises screening the spectral cell or the group of spectral cells comprising the antigens D, C, E, C, E, Jka, Jkb, M, N, S, S, Fya, Fyb, Lea, Leb, Mia, K, K, Kpa, Kpb, P1 and Dia.
Preferably, the screening method includes, but is not limited to, the saline method, the papain method, the indirect Coombs method, and neutralization, absorption, and diffusion.
In one embodiment of the present invention, the preparation method comprises the following steps:
selecting volunteers which are healthy and free of acute and chronic diseases and infectious diseases;
according to the blood type and the checking condition, determining the antigen type by adopting a saline method, a papain method, an indirect Coombs method and a neutralization, absorption and diffusion test;
screening the spectral cells or groups of spectral cells comprising antigens of the Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego and/or Lewis systems;
obtaining a composition of antibody-identified profiling cells.
The invention further provides a method for screening or identifying the serum irregular antibody, which comprises screening or identifying the antibody by using the composition of the antibody identification spectrum cell prepared by the invention.
Preferably, the method further comprises the step of screening and identifying by using methodology (saline method, papain method, indirect Coombs method and neutralization absorption, diffusion) or antibody characterization in combination with the composition of the profiling cells identified by the antibody of the present invention.
Preferably, it includes, but is not limited to, anti-human globulin assay, manual coacervation amine method or microcolumn gel card method.
Preferably, the anti-human globulin test method comprises the steps of taking serum of a person to be detected, and adding spectral cells; and (4) observing whether the agglutination reaction exists or not by centrifugation, observing whether the agglutination reaction exists or not at constant temperature, washing, adding Anti-IgG, observing whether the agglutination reaction exists or not, and determining the type of the irregular antibody.
Preferably, the centrifugation is 3400rpm centrifugation for 15 s.
Preferably, the constant temperature is 30min in a constant temperature tank at 37 ℃.
Preferably, the number of washing times is 1 to 5. Further preferably, the number of washing is 2 to 4.
In one embodiment of the invention, the anti-human globulin assay comprises the steps of:
(1) dropping 2 blood serum of a person to be detected into a test tube to serve as a test group (the number of the test groups is determined according to the combination of used spectral cells), and taking another empty test tube as a control group;
(2) adding 1 drop of each erythrocyte suspension into the test group, and adding 1 drop of 5% erythrocyte suspension into the control group;
(3) after mixing well, centrifuge at 3400rpm for 15 s. The presence or absence of agglutination was observed and the results were recorded.
(4) Placing in a thermostatic bath at 37 deg.C for 30 min. Centrifuge at 3400rpm for 15 s. The presence or absence of agglutination was observed and the results were recorded.
(5) After three washes Anti-IgG was added. The presence or absence of agglutination was observed and the results were recorded.
(6) And (5) determining the type of the irregular antibody in an exclusion method according to the 3 recording results of the steps (3) to (5).
Preferably, the manual amine condensation method comprises the steps of taking serum of a person to be detected, and adding spectral cells; mixing, adding LIM (low ion solution), mixing, and standing at room temperature; adding Polybrene (ammonium hexadimethrine bromide, Polybrene), mixing, and standing; centrifuging, pouring out the supernatant, and observing whether the agglutination phenomenon exists; and (4) observing whether an agglutination reaction exists after the resuspension is added, recording and determining the type of the irregular antibody.
Preferably, the standing time at room temperature is 0.5-2 min.
Preferably, the polybrene is added and then is kept still for 10 to 40 seconds.
Preferably, the amount of polybrene added is adjusted depending on the presence or absence of heparin.
Preferably, the centrifugation is 3400rpm centrifugation for 15 s.
In one embodiment of the present invention, the manual condensation method comprises the following steps:
1) dropping 2 blood serum of a person to be detected into a test tube to serve as a test group (the number of the test groups is determined according to the combination of used spectral cells), and taking another empty test tube as a control group;
2) adding 1 drop of spectral cells into test tubes of each test group, and adding 1 drop of red blood cell suspension of a person to be detected into a control group;
3) after mixing well, 0.65mL of LIM was added to each, mixed, and left to stand at room temperature for 1 min.
4) 2 drops of 0.05% Polybrene were added each and mixed, and then left to stand for 15 seconds. If the sample contains heparin, 6 drops of 0.05% Polybrene are added.
5) And centrifuging at 3400rpm for 15s, pouring out the supernatant, and slightly shaking the test tube to observe whether the agglutination phenomenon exists. Normally, agglutination should be observed, and if not, it should be done again.
6) 2 drops of each suspension were added, and the tube was gently shaken to observe the presence or absence of agglutination within 1 min. And the results are recorded.
Preferably, the micro-column gel cassette method comprises the steps of adding BLISSA liquid, serum of a person to be detected and screened cells into a reaction cavity of the anti-human globulin cassette in sequence, then incubating and centrifuging, judging agglutination or hemolysis results, and determining the types of irregular antibodies.
Preferably, the incubation conditions are at 37 ℃ for at least 10 min.
Preferably, the centrifugation time is 3-10 min.
In one embodiment of the present invention, the method of the present invention comprises the following steps:
(1) serum of a patient to be detected is taken, and red blood cells are prepared into 1.5% saline suspension.
(2) Taking out the reagent card (anti-human globulin card), and balancing to room temperature; before use, the microcolumn is observed by naked eyes to ensure that the microcolumn has no bubbles and no fault, and if the microcolumn has no bubbles or fault, the microcolumn is centrifuged to eliminate the bubbles or the fault.
(3) And marking a sample on the side with the bar code, and taking down the sealing strip. (the card hole of the removal seal must be used within one hour).
(4) 50 μ L of BLISSA solution was added to each reaction chamber. 40 μ L and 20 μ L of serum or plasma of a subject to be tested were added, respectively, followed by 1.5% suspension of selected cell I, II and III.
(5) Incubating at 37 deg.C for at least 10min, centrifuging for 5min, and reading agglutination or hemolysis result from both sides of the microcolumn.
The invention further provides application of the composition of the antibody identification spectrum cells in preparing products for screening or identifying the serum irregular antibodies.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only some embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1 clinical trial validation
The antigen distribution pattern of the composition of the spectrum cells identified by using 4 sets of antibodies consisting of the screened cells is shown in table 1.
TABLE 14 antigen distribution Pattern of compositions of antibody identification profiles of selected cell compositions
Figure 90351DEST_PATH_IMAGE025
Wherein, four sets of selected cells are from Diagnostic Grifols s.a., Serascan diana 3/Serascan diana 3P, 3052702, respectively; sanquin, Screening panel 123K 1148, 8000258847; shanghai blood biopharmaceutical, Inc., 20197031; and Jiangsu Libo pharmaceutical Biotechnology GmbH, 20190710.
1. Test procedure
(1) Serum was separated from the blood sample of the subject and the red blood cells were made into a 1.5% saline suspension.
(2) Taking out the reagent card (anti-human globulin card), and balancing to room temperature; before use, the microcolumn is observed by naked eyes to ensure that the microcolumn has no bubbles and no fault, and if the microcolumn has no bubbles or fault, the microcolumn is centrifuged to eliminate the bubbles or the fault.
(3) And marking a sample on the side with the bar code, and taking down the sealing strip. (the card hole of the removal seal must be used within one hour).
(4) 50 μ L of BLISSA solution was added to each reaction chamber. 40. mu.L of serum or plasma of the subject to be tested and 20. mu.L of 1.5% suspension of selected cell I, II and III were added, respectively.
(5) Incubation was performed at 37 ℃ for at least 10min, and agglutination or hemolysis results were read from both sides of the microcolumns after 5min centrifugation using a BioVue centrifuge.
The agglutination valence number of the combined screening cells reacting with the serum of the subject is recorded on a table, and the correct irregular antibody species is determined by a deletion method.
2. Test results
The positive identification results of the three-time ventricular evaluation anti-screening are shown in table 2, and the results show that the accuracy of the antibody screening and identification results of 15 samples is 100%. Meanwhile, the indoor quality evaluation scores of 2019 clinical blood transfusion compatibility detection tests made by the clinical laboratory center of the department of health are all AAA, wherein the laboratory code is 101028-7, the name of the laboratory is Beijing friendship hospital affiliated to capital medical university, the test date is 09 and 11 days in 2019, and the specific scores are shown in Table 3.
TABLE 2 Positive identification results of three-time ventricular mesentery evaluation screen
Figure 789841DEST_PATH_IMAGE026
TABLE 32019 summarization of quality assessment in the Chamber for clinical transfusion compatibility testing
Figure 418269DEST_PATH_IMAGE027
Example 2 clinical trial validation
The antigen distribution pattern of the composition of the spectrum cells is shown in tables 4 and 5 by using 3 sets of antibodies consisting of the screened cells.
TABLE 43 antigen distribution and test results for compositions of antibody identification profiles of selected cell compositions
Figure 719937DEST_PATH_IMAGE028
Wherein, the three sets of selected cells are from Diagnostic Grifols S.A., Serascan diana 3/Serascan diana 3P, 3052702, respectively; sanquin, Screening panel 123K 1148, 8000258847; and Shanghai blood biopharmaceutical GmbH, 20197031.
TABLE 53 antigen distribution and test results for compositions of antibody identification profiles of selected cell compositions
Figure 408407DEST_PATH_IMAGE029
Wherein, the three sets of selected cells are from Diagnostic Grifols S.A., Serascan diana 3/Serascan diana 3P, 3052702, respectively; sanquin, Screening panel 123K 1148, 8000258847; and Shanghai blood biopharmaceutical GmbH, 20197031.
Example 3 identification of clinical practice results
Clinical patients were screened for blood group irregularities according to the test procedure of example 1 and the composition of the spectral cells of the antigen distribution pattern, and the distribution of 32 screened irregular antibodies over the clinical year is shown in table 6. The results showed 100% accuracy.
TABLE 632 results of irregular antibody identification
Figure 529947DEST_PATH_IMAGE030
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.

Claims (5)

1. A composition of antibody-identified profiling cells, wherein said composition comprises at least 2 sets of selected cells, each set of selected cells comprising a three-cell panel, said composition comprising antigens of Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego, and/or Lewis systems; the composition contains D, C, E, C, E and Jka、Jkb、M、N、S、s、Fya、Fyb、LeaAnd/or Leb(ii) a The composition also contains Mia, K, K and Kpa、KpbP1 and/or Dia(ii) a Wherein, the antigen distribution pattern of 2 sets of screened cells is selected from any one of the following groups:
a）
Figure 60445DEST_PATH_IMAGE001
b）
Figure 350612DEST_PATH_IMAGE002
c）
Figure 230844DEST_PATH_IMAGE003
d）
Figure 104997DEST_PATH_IMAGE004
e）
Figure 463297DEST_PATH_IMAGE005
f）
Figure 670287DEST_PATH_IMAGE006
g）
Figure 721420DEST_PATH_IMAGE007
h）
Figure 82869DEST_PATH_IMAGE008
i）
Figure 979280DEST_PATH_IMAGE009
j）
Figure 978460DEST_PATH_IMAGE010
。
2. a composition of antibody-identified profiling cells, wherein said composition comprises at least 3 sets of selected cells, each set of selected cells comprising a three-cell panel, said composition comprising antigens of Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego, and/or Lewis systems; the composition contains D, C, E, C, E and Jka、Jkb、M、N、S、s、Fya、Fyb、LeaAnd/or Leb(ii) a The composition also contains Mia, K, K and Kpa、KpbP1 and/or Dia(ii) a Wherein, the antigen distribution pattern of the 3 sets of screened cells is selected from any one of the following groups:
（1）
Figure 200494DEST_PATH_IMAGE011
（2）
Figure 783660DEST_PATH_IMAGE012
（3）
Figure 749342DEST_PATH_IMAGE013
（4）
Figure 868608DEST_PATH_IMAGE014
（5）
Figure 995964DEST_PATH_IMAGE015
（6）
Figure 895787DEST_PATH_IMAGE016
（7）
Figure 898116DEST_PATH_IMAGE017
（8）
Figure 75150DEST_PATH_IMAGE018
（9）
Figure 373407DEST_PATH_IMAGE019
。
3. a composition of antibody-identified profiling cells, wherein said composition comprises at least 4 sets of selected cells, each set of selected cells comprising a three-cell panel, said composition comprising antigens of Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego, and/or Lewis systems; the composition contains D, C, E, C, E and Jka、Jkb、M、N、S、s、Fya、Fyb、LeaAnd/or Leb(ii) a The composition also contains Mia, K, K and Kpa、KpbP1 and/or Dia(ii) a Wherein, the antigen distribution pattern of the 4 sets of screened cells is selected from any one of the following groups:
A）
Figure 760526DEST_PATH_IMAGE020
B）
Figure 566546DEST_PATH_IMAGE021
C）
Figure 457142DEST_PATH_IMAGE022
D）
Figure 191880DEST_PATH_IMAGE023
。
4. a method of preparing a composition according to any one of claims 1 to 3, comprising screening the set or panels of spectral cells for antigens comprising the Rh-hr, Kidd, MNSs, Duffy, Kell, P, Diego and/or Lewis systems.
5. Use of a composition according to any one of claims 1 to 3 in the preparation of a product for screening or identification of antibodies against serum irregularities.
CN201911310553.6A 2019-12-18 2019-12-18 Composition for identifying spectrum cells by using antibody Active CN110736832B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911310553.6A CN110736832B (en) 2019-12-18 2019-12-18 Composition for identifying spectrum cells by using antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911310553.6A CN110736832B (en) 2019-12-18 2019-12-18 Composition for identifying spectrum cells by using antibody

Publications (2)

Publication Number Publication Date
CN110736832A CN110736832A (en) 2020-01-31
CN110736832B true CN110736832B (en) 2020-04-10

Family

ID=69274574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911310553.6A Active CN110736832B (en) 2019-12-18 2019-12-18 Composition for identifying spectrum cells by using antibody

Country Status (1)

Country Link
CN (1) CN110736832B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748129A (en) * 1984-08-28 1988-05-31 Snytex (U.S.A.) Inc. Assay method employing fluorescent cell incorporative dye
CN102175877A (en) * 2010-12-31 2011-09-07 周胜利 Method for trace, fast and accurate detection of human erythrocyte antigen and antibodies in serum
CN102338800A (en) * 2011-05-25 2012-02-01 上海血液生物医药有限责任公司 Antibody screening erythrocyte kit
CN107202898A (en) * 2017-06-15 2017-09-26 迈克生物股份有限公司 Kit for Shanghai irregular antibody

Also Published As

Publication number Publication date
CN110736832A (en) 2020-01-31

Similar Documents

Publication Publication Date Title
Parker et al. The direct antiglobulin test: indications, interpretation, and pitfalls
Frontroth et al. Ristocetin-induced platelet aggregation (RIPA) and RIPA mixing studies
Kessler et al. Dog erythrocyte antigens 1.1, 1.2, 3, 4, 7, and Dal blood typing and cross‐matching by gel column technique
CN106947835B (en) The identification method of ebv infection lymphocyte subgroup and its application
Moore et al. Haematology
JPH061272B2 (en) Method and apparatus for measuring degree of reaction between antigen and white blood cell antibody
Roback et al. An automatable format for accurate immunohematology testing by flow cytometry
Harris et al. Effect of sample storage on blood crossmatching in horses
CN110174519B (en) Confluent-detection type erythrocyte blood type irregular antibody detection kit based on solid-phase agglutination technology and preparation method thereof
CN102426258B (en) Positive serum national standard substance used for newcastle disease hemagglutination inhibition test and preparation method thereof
CN104698193A (en) Method for identifying blood group of rhesus monkey
CN113156143A (en) Blood group irregular antibody specificity identification method and reagent thereof
CN110736832B (en) Composition for identifying spectrum cells by using antibody
US20200110097A1 (en) Immunoassay for simultaneously screening anti-platelet antibodies and performing platelets cross matching and test apparatus for carrying out same
Trudell Detection and identification of antibodies
CN111983236A (en) Gamma interferon release method for detecting SARS-COV-2 infection of novel coronavirus
Judd et al. Reactivity of FDA-approved anti-D reagents with partial D red blood cells
Crespo et al. Interpretation of laboratory results and values
CN116148463A (en) Magnetic bead-antibody-membrane glycoprotein complex, application and kit
Roback et al. Performance and reliability of a benchtop automated instrument for transfusion testing: a comparative multicenter clinical study in the US population
CN1871519A (en) Quick test for the diagnosis of alzheimer' disease
Ritzmann et al. The Sia euglobulin test: a re-evaluation
Melo et al. Twelve years of the Brazilian External Quality Assessment Program in Immunohematology: benefits of the program
CN1278123C (en) Detecting method for blood compounding test before transfusion
Keikhaei et al. Frequency of Red Cell Alloimmunization in Patients with Thalassemia Major: A Report from the Southwest of Iran

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant